AT1022

DB04995ExperimentalSmall molecule

AT1022 is a hydromorphone skin patch designed to provide rapid and sustained delivery of a potent opiate for the management of severe pain. AT1022 incorporates PassPort(TM) system, developed to deliver... AT1022 incorporates PassPort(TM) system, developed to deliver protein and peptide drugs, small-molecule drugs, genes and vaccines across the skin for local and systemic effect.

Primary indication: Investigated for use/treatment in pain (acute or chronic).Curator reviewed
Code names: AT1022

Which companies are running trials of AT1022, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account